A bullish flag pattern has emerged in the chart of Dexcom Inc. (NASDAQ: DXCM), where the stock is just under a resistance line. If DXCM breaks through this level, a breakout could occur. Read more if ...

Medical device maker DexCom (NASDAQ: DXCM) has been trading in a fairly tight range recently, holding gains from the company’s third-quarter report in late October. The stock is up 16.33% in the past ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...

Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eighteen brokerages that are presently covering the firm, Marketbeat reports.

DexCom, Inc. (NASDAQ:DXCM – Get Free Report)’s stock price gapped up prior to trading on Friday after Canaccord Genuity Group raised their price target on the stock from $103.00 to $106.00. The stock ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...